For the millions of adults living with coronary artery disease who have undergone stenting, one of the most consequential clinical decisions is how long to continue dual antiplatelet therapy — a question where getting the answer wrong carries real costs in either direction. This editorial published in the New England Journal of Medicine addresses the persistent tension clinicians face when extending DAPT beyond standard durations: reduced ischemic events on one side of the scale, increased bleeding risk on the other.
The editorial engages with the core tradeoff at the heart of DAPT duration research: longer therapy suppresses platelet aggregation more completely, lowering the probability of late stent thrombosis and recurrent myocardial infarction, but simultaneously elevates hemorrhagic risk — including gastrointestinal and intracranial bleeding — that independently drives morbidity and mortality. The piece appears in the context of ongoing trials and risk-stratification tools attempting to identify which patient subgroups derive net benefit from prolonged antiplatelet regimens versus those for whom early de-escalation is safer.
This editorial lands in a research space that has been actively contested for over a decade. Landmark trials such as DAPT, PEGASUS-TIMI 54, and TWILIGHT have each refined the picture but left substantial clinical uncertainty, particularly for high-ischemic-risk patients who also carry elevated bleeding burden. What makes this commentary relevant beyond cardiology is its broader implication: precision medicine in secondary prevention requires moving away from universal duration rules toward individualized risk profiling. For health-conscious adults managing cardiovascular risk factors, this reinforces that antiplatelet decisions are not set-and-forget — they warrant periodic reassessment as a patient's bleeding risk, renal function, and comorbidity profile evolve. As an editorial rather than primary data, this piece is appropriately considered contextual and interpretive rather than a paradigm shift on its own terms.